Skip to main content

Table 1 Characteristics of included studies in the meta-analysis

From: Prognostic and clinicopathological significance of SNHG20 in human cancers: a meta-analysis

Author Year Study region Recruitment time Cancer type Age (%) No. (high/low) Outcome Detection method Cut-off value Source of HR NOS score
Li et al. 2016 China 2006–2011 Colorectal cancer ≥ 65 (52.3%) 107 (54/53) OS qRT-PCR NA Data in paper 7
Li et al. 2017 China 2007–2011 Hepatocellular carcinoma > 65 (25.0%) 96 (50/46) OS qRT-PCR Median Survival curves 8
Wang et al. 2018 China 2016–2017 Osteosarcoma ≥ 18 (88.2%) 32 (18/14) OS qRT-PCR Median Survival curves 8
Zhang1 et al. 2016 China 2006–2009 Hepatocellular carcinoma > 55 (41.7%) 144 (98/46) OS DFS ISH NA Data in paper 6
Cui et al. 2018 China 2012–2014 Gastric cancer > 55 (50.0%) 56 (28/28) OS DFS qRT-PCR NA Survival curves 6
Chen et al. 2017 China 2013–2015 Lung cancer > 65 (52.4%) 42 (21/21) OS PFS qRT-PCR Median Survival curves 7
Guo et al. 2018 China NA Cervical cancer ≥ 45 (47.3%) 93 (47/46) OS qRT-PCR NA Survival curves 7
Zhang et al. 2018 China NA Esophageal carcinoma ≥ 60 (67.5%) 80 (37/43) OS qRT-PCR Median Survival curves 6
Gao et al. 2018 China 2008–2013 Oral carcinoma > 60 (45.0%) 40 (20/20) OS qRT-PCR NA Data in paper 8
Gao et al. 2019 China NA Glioma ≥ 60 (30.8%) 78 (33/45) OS qRT-PCR Mean Survival curves 8
Sun et al. 2018 China 2011–2013 Nasopharyngeal carcinoma > 50 (52.7%) 55 (28/27) OS qRT-PCR Median Survival curves 6
Wang et al. 2019 China NA Epithelial ovarian cancer > 55 (43.3%) 60 (38/22) OS qRT-PCR NA Survival curves 6
Zhang2 et al. 2018 China NA Osteosarcoma > 18 (61.4%) 140 (70/70) OS qRT-PCR NA Data in paper 7
Li1 et al. 2019 China NA Laryngeal carcinoma ≥ 60 (58.9%) 56 (28/28) OS qRT-PCR NA Survival curves 8
Li2 et al. 2019 China 2011–2017 Glioma ≥ 50 (52.8%) 108 (54/54) OS RFS qRT-PCR Median Data in paper 6
  1. NO number, HR hazard ratio, NOS Newcastle–Ottawa Scale, NA not available, OS overall survival, DFS disease-free survival, RFS recurrence-free survival, PFS progression-free survival, qRT-PCR quantitative reverse transcription polymerase chain reaction, ISH in situ hybridization